Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled H057 for Acute Exacerbations of Bronchiectasis
NCT06958861Phase 2Not yet recruiting
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of H-057 in bronchiectasis (3 arms), sponsored by Shanghai Huilun Pharmaceutical Co., Ltd. Primary endpoint: Quality-of-Life Bronchiectasis Respiratory Symptom Score at Day 15. Planned start May 2025; status: not yet recruiting.
02
Drugs
H-057
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT06958861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958861.